<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719403</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY02000798</org_study_id>
    <nct_id>NCT04719403</nct_id>
  </id_info>
  <brief_title>Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers</brief_title>
  <official_title>Determining the Feasibility, Acceptability, and Potential Effectiveness of Sharing Video Recordings of Multidisciplinary ALS Clinics With Patients and Their Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Diamond Endowment Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate the feasibility and acceptability of routine&#xD;
      sharing of clinic video recordings with patients and caregivers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Enrollment (Feasibility)</measure>
    <time_frame>Study Completion, an average of 1 year</time_frame>
    <description>Meeting the targeted recruitment number and rate (two patients per month over a 12 month period)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention Fidelity (Feasibility)</measure>
    <time_frame>Three months</time_frame>
    <description>The proportion of ALS MDC (multidisciplinary clinic) patients in the intervention arm that received the VIDEO intervention with full adherence to a pre-defined protocol fidelity checklist. Any deviations will be documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient use of the Intervention (Acceptability)</measure>
    <time_frame>Three months</time_frame>
    <description>The proportion of ALS MDC (multidisciplinary clinic) patients in the intervention arm who used the recording between the day of receipt and the three-month follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Satisfaction, as measured by the Patient Satisfaction Questionnaire-18 (PSQ-18)</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on an 18-item, 5-level scale, with a score of 1 indicating &quot;strongly agree&quot; and a score of 5 indicating &quot;Strongly Disagree&quot;. Scores range from 18 to 90, with lower scores indicating higher levels of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in adherence to treatment, as measured by the Medical Outcomes Study - General Adherence</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on a 5-item, 6-level scale, with a score of 1 indicating &quot;None of the time&quot; and a score of 6 indicating &quot;All of the time&quot;. Scores range from 6 to 30, with higher scores indicating higher levels of adherence. Items 1 and 3 are scored in reverse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in adherence to medications, as measured by the Adherence to Refills and Medications Scale - 7 (ARMS-7)</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on a 7-item, 4-level scale, with a score of 1 indicating &quot;None&quot; and a score of 4 indicating &quot;All&quot;. Scores range from 7 to 28, with lower scores indicating higher levels of adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in adherence to physical therapy, as measured by the Exercise Adherence Rating Scale (EARS)</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on a 6-item, 5-level scale, with 0 indicating &quot;Completely agree&quot; and 4 indicating &quot;Completely disagree&quot;. Scores range from 0 to 30, where a higher score indicates a higher level of adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anxiety, as measured by the Generalized Anxiety Disorder - 7 (GAD-7)</measure>
    <time_frame>Baseline, three months</time_frame>
    <description>Scores are based on a 7-item, 4-level scale with 0 indicating &quot;Not at all&quot; and 3 indicating &quot;Nearly every day&quot;. Higher scores indicate higher levels of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional status, as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on a 13-item, 5-level scale, with 0 indicating low function and 4 indicating high functioning, and one item as &quot;yes/no&quot;. Scores range from 0 to 48, with high scores indicating higher levels of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in depression, as measured by the Patient Health Questionnaire - 8 (PHQ-8)</measure>
    <time_frame>Baseline, three months</time_frame>
    <description>Scores are based on a 8-item, 4-level scale with 0 indicating &quot;Not at all&quot; and 3 indicating &quot;Nearly every day&quot;. Higher scores indicate higher levels of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Communication in the Visit, as measured by the Interpersonal Processes of Care (IPC)</measure>
    <time_frame>One week</time_frame>
    <description>Scores are based on an 18-item, 5-level scale with 1 indicating &quot;Never&quot; and 5 indicating &quot;Always&quot;. Scores range from 18 to 90, with higher scores indicating higher levels of communication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of literacy, as measured by the Single Item Literacy Screener</measure>
    <time_frame>Baseline</time_frame>
    <description>Scores are measured on a single item, 5-level scale. Scores range from 1 to 5, with higher scores indicating higher levels of literacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver burden, as measured by the Burden Scale for Family Caregivers - Short (BSFC-s)</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are based on a 10-item, 4-level scale, with 0 indicating strongly disagree and 3 indicating strongly agree. Scores range from 0 to 30, with higher scores indicate higher levels of burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in caregiver preparedness, as measured by the Preparedness for Caregiving Scale</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are based on a 9-item, 5-level scale, with 0 indicating not at all prepared, and 4 indicating very well prepared. Scores range from 0 to 45, with higher scores indicating higher levels of preparedness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-efficacy, as measured by the Self Efficacy for Managing Chronic Disease scale</measure>
    <time_frame>Baseline, one week, three months</time_frame>
    <description>Scores are measured on 6x 10-item scales. Scores range from 0 to 60, with higher scores indicating higher levels of self-efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the Intervention, as measured by the Feasibility of Intervention Metric (FIM)</measure>
    <time_frame>Three months from baseline</time_frame>
    <description>Scores are measured on a 4-item, 5-level scale, with a score of 1 indicating &quot;completely disagree&quot; and 5 indicating &quot;completely agree&quot;. Scores range from 4 to 20, with higher scores indicating higher levels of feasibility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the Intervention, as measured by the Acceptability of Intervention Metric (AIM)</measure>
    <time_frame>Three months from baseline</time_frame>
    <description>Scores are measured on a 4-item, 5-level scale, with a score of 1 indicating &quot;completely disagree&quot; and 5 indicating &quot;completely agree&quot;. Scores range from 4 to 20, with higher scores indicating higher levels of acceptability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>VIDEO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive access to video recordings of their clinic visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive usual care (UC), which is their normal clinic visit and written after-visit summary</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HealthPAL</intervention_name>
    <description>Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.</description>
    <arm_group_label>VIDEO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed and primarily treated for Amyotrophic Lateral Sclerosis (ALS)&#xD;
&#xD;
          -  Aged 18 years or greater&#xD;
&#xD;
          -  Can communicate in English (verbally, on a computer, or with assistance)&#xD;
&#xD;
          -  Have email&#xD;
&#xD;
          -  Have internet access&#xD;
&#xD;
          -  Willing to have their multidisciplinary clinic visit audio/video recorded for a 3&#xD;
             month period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those without the capacity to provide consent, either themselves or via proxy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul J Barr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reed WR Bratches, MPH</last_name>
    <phone>6312591504</phone>
    <email>reed.w.bratches.gr@dartmouth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan M Tarczewski</last_name>
    <phone>603-646-7066</phone>
    <email>susan.m.tarczewski@dartmouth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reed WR Bratches, MPH</last_name>
      <phone>631-259-1504</phone>
      <email>reed.w.bratches.gr@dartmouth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Tarczewski</last_name>
      <phone>603-646-7066</phone>
      <email>susan.m.tarczewski@dartmouth.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Paul J. Barr</investigator_full_name>
    <investigator_title>Associate Professor, The Dartmouth Institute for Health Policy and Clinical Practice</investigator_title>
  </responsible_party>
  <keyword>neurology</keyword>
  <keyword>health communications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

